Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global ...

Key market opportunities include the rising prevalence of chronic diseases and increased regulatory approvals driving demand ...

The latest OXB agreement will help advance the company’s CAR-T therapies and provide a “reliable, scalable manufacturing ...

Bristol Myers stock is volatile ahead of earnings as investors weighed its expanded OXB manufacturing deal and recent bullish ...

OXB to become commercial manufacturer of lentiviral vectors for Bristol Myers Squibb (BMS) CAR-T programmesMulti-year agreement with five-year ...

Viral vectors are a key component of many advanced gene therapies and vaccines, but reliable, large-scale manufacturing remains a significant challenge. Continued innovation in vector design, cell ...

OXB and Bristol Myers Squibb (BMS) are expanding a partnership regarding manufacture and supply of lentiviral vectors for BMS’ CAR-T programs.

Thermo Fisher Scientific will close a manufacturing facility in Franklin, Massachusetts, and eliminate up to 80 positions.

NanoMosaic's technology is designed to support upstream and downstream process development, quality control, and release testing.

As climate change extends mosquito habitats and vector-borne diseases remain a critical concern, industry analysis suggests that DEET production capacity and supply chain resilience are receiving ...

To support rising global demand, CMT expanded its production capabilities through strategic investment in operations and resources. In addition to its established manufacturing site in the United ...